Spontaneously remitting insulin autoimmune syndrome in a patient taking alpha-lipoic acid

D Cappellani, C Sardella, M C Campopiano, A Falorni, P Marchetti and E Macchia

Summary

Insulin autoimmune syndrome (IAS), or Hirata disease, is a rare hypoglycaemic disorder caused by the presence of high titer of insulin autoantibodies (IAA) in patients without previous exposure to exogenous insulin. Even though its pathogenesis is not fully understood, striking evidences link IAS to previous exposure to sulphydryl-containing medications, like alpha-lipoic acid, a widely used nutritional supplement. Although challenging, a careful differential diagnosis from other causes of hyperinsulinaemic hypoglycaemia (such as insulinoma) is mandatory, since these conditions require different therapeutic approaches. In the present study, we report a 35-year-old woman originally from Sri Lanka who was referred to our University Hospital on suspicion of occult insulinoma. Her medical history was positive for endometriosis, treated with estroprogestins and alpha-lipoic acid. The latter supplement was begun 2 weeks before the first hypoglycaemic episode. Our tests confirmed the presence of hypoglycaemia associated with high insulin and C-peptide concentrations. When insulin concentrations were compared using different assays, the results were significantly different. Moreover, insulin values significantly decreased after precipitation with polyethylene glycol. An assay for IAA proved positive (530 U/mL). A genetic analysis revealed the presence of HLA-DRB1*04,15, an immunogenetic determinant associated with IAS. On the basis of clinical data we avoided a first-line approach with immunosuppressive treatments, and the patient was advised to modify her diet, with the introduction of frequent low-caloric meals. During follow-up evaluations, glucose levels (registered through a flash glucose monitoring system) resulted progressively more stable. IAA titer progressively decreased, being undetectable by the fifteenth month, thus indicating the remission of the IAS.

Learning points:

- Insulin autoimmune syndrome (IAS) is a rare cause of hyperinsulinaemic hypoglycaemia, whose prevalence is higher in East Asian populations due to the higher prevalence of specific immunogenetic determinants. Nevertheless, an increasing number of IAS cases is being reported worldwide, due to the wide diffusion of medications such as alpha-lipoic acid.
- Differential diagnosis of IAS from other causes of hyperinsulinemic hypoglycaemia is challenging. Even though many tests can be suggestive of IAS, the gold standard remains the detection of IAAs, despite that dedicated commercial kits are not widely available.
- The therapeutic approach to IAS is problematic. As a matter of fact IAS is often a self-remitting disease, but sometimes needs aggressive immunosuppression. The benefits and risks of any therapeutic choice should be carefully weighted and tailored on the single patient.
Insulin autoimmune syndrome (IAS) is a rare disease, firstly described by Hirata and colleagues in 1970 (1) and characterised by spontaneous hypoglycaemic episodes in the presence of high titer of insulin autoantibodies (IAAs) in patients without previous exposure to exogenous insulin. Hypoglycaemic episodes can occur during fast or after a meal and can be life-threatening.

Mostly due to immunogenetic determinants (2), this condition is the third leading cause of hypoglycaemia in Japan, but case reports or case series are increasingly being published outside this country and in non-Asian populations. Striking evidences link this syndrome to previous exposure to some medications (3), including methimazole, glutathione or alpha-lipoic acid. Like insulin itself, all these drugs are sulphhydryl compounds; as a consequence, a molecular mimicry mechanism can be advocated as pathogenetic.

Differential diagnosis from insulinoma is sometimes challenging, but it is important in order to avoid invasive procedures and inappropriate abdominal surgery. The management of IAS is challenging too: on the one side, a high percentage of spontaneous remission is described (estimated in 60–70% of the untreated patients) (4), on the other side, the potential life-threatening nature of the disease warrants pharmacologic immunosuppressive approaches that are not free from side effects.

Case presentation

A 35-year-old woman originally from Sri Lanka presented to the Emergency Department of a peripheral primary care hospital for the sudden occurrence of neurological symptoms (asthenia, blurred vision, aphasia, loss of coordination and partial amnesia). Given the finding of a blood glucose of 38 mg/dL, the patient was treated with intravenous glucose administration with prompt resolution of symptoms. For the recurrence of hypoglycaemia during the short-stay observation period, the patient was admitted to the local General Medicine Unit.

A blood test performed during a subsequent hypoglycaemic episode revealed an insulin value higher than 1000 µU/mL with a C-peptide of 31.8 ng/mL. Imaging studies (including abdominal echography, abdominal CT, abdominal RM, 68Ga-DOTATOC PET) did not reveal any lesion suggestive for insulin-secreting tumours. In the belief of an occult insulinoma, the patient was then transferred to our University Hospital for further evaluation and possible surgical management.

Investigation

The clinical history revealed no previous significant illnesses, except for endometriosis treated with estroprogestins: the patient had recently changed the route of administration of such medications (previously oral route, currently vaginal route) and had begun a cycle of alpha-lipoic acid just 2 weeks before the first hypoglycaemic episode. Physical examination resulted unremarkable: patient height was 1.65 m, weight was 66 kg and the resulting BMI was 24.2 kg/m².

At baseline, routine tests of blood glucose showed 129 mg/dL and blood insulin 2465 µU/mL; the latter result was obtained using an immunochemiluminometric assay (ICMA). As previously described (5) a polyethylene glycol (PEG) precipitation test was performed on various insulin samples, revealing a ten-fold reduction in insulin values (e.g. from 2465 to 256 µU/mL and from 2576 to 128.87 µU/mL respectively).

As we suspected an IAS, a blood sample for diagnosis of IAA was drawn. The assay of these autoantibodies gave a frankly positive result (530 U/mL; normal values <0.4) (Fig. 1). At the same time, a genetic analysis was performed, which revealed the presence of HLA-DRB1*04,15, an immunogenetic determinant already described as associated with IAS (2).

Treatment

The patient’s diet was modified with the introduction of high frequent and low-caloric meals, rich in simple sugars, which was associated to reduced hypoglycaemic episodes. Furthermore, a flash glucose monitoring (FGM) system FreeStyle Libre (Abbott) was inserted, demonstrating a progressively more stable glucose level.

Taking into account the high percentage of spontaneous remission of this syndrome, the absence of other associated autoimmune diseases, the effectiveness
of the diet modification according to the FGM and the wish of the patient, we decided not to actively treat the condition, avoiding at least initially immunosuppressive treatments. The patient was dismissed with the indication to continue FGM while following the same diet and repeating blood samples for IAA.

**Outcome and follow-up**

The patient came back at months 2, 6, 11 and 15 during the follow-up. Glycaemic levels detected using FGM were proved durably in the acceptable range, without significant hypoglycaemic episodes (Fig. 2). At 6 months from the diagnosis, IAA titer resulted 51 U/mL, with a reduction of 90.4% from the baseline (Fig. 1).

The patient was then advised to gradually give up the prescribed diet, going back to the pre-admission eating habits. IAA titer gradually decreased, and by the fifteenth month were completely undetectable, indicating the complete remission of the disease (Fig. 1).

**Discussion**

This case report provides insight into important issues in diagnosis and management of IAS. IAS is a form of
Insulin autoimmune syndrome

D Cappellani and others

Insulin autoimmune syndrome and α-lipoic acid

levels registered with different assays were suggestive for endogenous hyperinsulinemic hypoglycaemia. The gold standard for the diagnosis of IAS is the detection of IAA, but commercial kits for the detection of IAA are not widely available. As a consequence, alternative diagnostic tools were proposed, such as precipitation with PEG, followed by insulin assay in the supernatant.

In our patient, a series of different diagnostic tools were used for the diagnosis of IAS. The baseline biochemical features were suggestive for endogenous hyperinsulinemic hypoglycemia. Contemporarily, the difference in insulin levels registered with different assays were suggestive for a laboratory interference and/or for the presence of IAA complexes, as successively demonstrated by precipitation with PEG. Due to the high suspicion of the presence of IAS, we performed an assay for IAA, and their presence supported the diagnosis. During the follow-up, IAs were assayed again, revealing a progressive lowering in autoantibody titer. This result was in line with the clinical features reported by the patient and with the glucose profiles registered by the FGM system.

Despite the description of frequent spontaneous remission, IAS sometimes needs immunosuppressive treatments. A rational first-line approach consists in small frequent meals with low carbohydrate content in order to reduce post-prandial hyperglycaemia and the consequent stimulus to insulin secretion. According to the published guidelines, the medical treatment of autoimmune hypoglycaemia is problematic. Glucocorticoids can be the first medication of choice, where necessary. Among the other second-line therapeutic options, immunosuppressants (azathioprine and 6-mercaptopurine), monoclonal antibodies (rituximab), plasmapheresis and strategies to reduce insulin release (somatostatin analogues, diazoxide and pancreatectomy), all demonstrated varying efficacy in the management of IAS.

In conclusion, IAS is a rare condition, defined by the presence of IAA which are the mediators of hyperinsulinemic hypoglycaemia. IAS is interpreted as an autoimmune disease, even though its pathophysiology is still not fully understood. Specifically, the mechanisms underneath the development of IAA are not completely clear and the genesis of hypoglycaemia has not been explained in detail yet. Moreover, it is still unclear why an autoimmune disease undergoes a spontaneous resolution in the majority of cases even though the antigen (insulin itself) is still present. We wonder whether this condition
could be considered an immune-mediated disease rather than an autoimmune disease.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Patient consent
Written informed consent for publication of clinical data was obtained from the patient.

Author contribution statement
D Cappellani, C Sardella, M C Campopiano, P Marchetti and E Macchia were involved in the direct care of the patient. A Falorni was responsible for the IAA assays. D Cappellani and M C Campopiano revised the clinical charts. D Cappellani wrote the initial draft. C Sardella, A Falorni, P Marchetti, E Macchia edited the manuscript. A Falorni, P Marchetti and E Macchia reviewed and approved the final version of the manuscript.

References
1 Hirata Y, Ishizu H, Ouchi N, Motomura S, Abe M & Hara Y. Insulin autoimmunity in a case of spontaneous hypoglycemia. Journal of the Japan Diabetes Society 1970 13 312–320.
2 Uchigata Y, Tokunaga K, Nepom G, Bannai M, Kuwata S, Dozio N, Benson EA, Ronningen KS, Spinas GA, Tadokoro K, et al. Differential immunogenetic determinants of polyclonal insulin autoimmune syndrome (Hirata's disease) and monoclonal insulin autoimmune syndrome. Diabetes 1995 44 1227–1232. (https://doi.org/10.2337/diab.44.10.1227)
3 Uchigata Y, Hirata Y & Iwamoto Y. Drug-induced insulin autoimmune syndrome. Diabetes Research and Clinical Practice 2009 83 e19–e20. (https://doi.org/10.1016/j.diabres.2008.10.015)
4 Uchigata Y, Eguchi Y, Takayama-Hasumi S & Omori Y. Insulin autoimmune syndrome (Hirata disease): clinical features and epidemiology in Japan. Diabetes Research and Clinical Practice 1994 22 89–94. (https://doi.org/10.1016/0168-8227(94)90040-X)
5 Gullo D, Evans JL, Sortino G, Goldfine ID & Vigneri R. Insulin autoimmune syndrome (Hirata disease) in European Caucasians taking alpha-lipoic acid. Clinical Endocrinology 2014 81 204–209. (https://doi.org/10.1111/cen.12334)
6 Ismail AA. The insulin autoimmune syndrome (IAS) as a cause of hypoglycaemia: an update on the pathophysiology, biochemical investigations and diagnosis. Clinical Chemistry and Laboratory Medicine 2016 54 1715–1724. (https://doi.org/10.1515/cclm-2015-1255)
7 Uchigata Y, Omori Y, Nieda M, Kuwata S, Tokunaga K & Juji T. HLA-DR4 genotype and insulin-processing in insulin autoimmune syndrome. Lancet 1992 340 1467. (https://doi.org/10.1016/0140-6736(92)92654-X)
8 Hirata Y & Uchigata Y. Insulin autoimmune syndrome in Japan. Diabetes Research and Clinical Practice 1994 24 (Supplement) S153–S157. (https://doi.org/10.1016/0168-8227(94)90243-7)
9 Redmon JB & Nuttall FQ. Autoimmune hypoglycemia. Endocrinology and Metabolism Clinics of North America. 1999 28 603–618, vii. (https://doi.org/10.1016/S0889-8529(05)70090-6)
10 Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER & Service FJ. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism 2009 94 709–728. (https://doi.org/10.1210/jc.2008-1410)
11 Wong SL, Priestman A & Holmes DT. Recurrent hypoglycemia from insulin autoimmune syndrome. Journal of General Internal Medicine 2014 29 250–254. (https://doi.org/10.1007/s11606-013-2588-9)
12 Saxon DR, McDermott MT & Michels AW. Novel management of insulin autoimmune syndrome with rituximab and continuous glucose monitoring. Journal of Clinical Endocrinology and Metabolism 2016 101 1931–1934. (https://doi.org/10.1210/jc.2016-1097)